Zentalis Pharmaceuticals has dosed the first patient in the Phase 3 ASPENOVA trial, testing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial compares azenosertib to standard chemotherapy and aims to confirm benefits seen in earlier Phase 2 studies, supporting full FDA approval. The ASPENOVA study enrolls about 420 patients globally and focuses on progression-free survival as the primary endpoint. Results from the ongoing Phase 2 DENALI trial, expected by the end of 2026, may lead to accelerated approval, while ASPENOVA will provide confirmatory data for full approval.
In 2026, the United States saw its share of Bitcoin's total mining hashrate decline by about 0.823%, losing roughly 55 exahash per second (EH/s), though it remains the largest miner globally. Meanwhile, China and Russia increased their share of the g...
Meta has agreed to an $18 billion legal settlement, which translates to about $1 billion per year—an amount negligible compared to its substantial revenue and earnings. The settlement resolves regulatory uncertainties, allowing Meta to focus on its c...
Genius Group, after selling its entire Bitcoin reserve to repay $8.5 million in debt, plans to rebuild its Bitcoin and AI treasuries to a combined $1.6 billion by fiscal year 2031. The company aims to grow total assets to $2 billion and will fund tre...
Veteran trader Peter Brandt revealed he remains long on Bitcoin even as the cryptocurrency struggles to break above the key resistance zone around $82,000. Bitcoin recently climbed above $80,000 but faced strong selling pressure, causing a pullback. ...
Grayscale's Zach Pandl highlights that the US Treasury's bond repurchases aim to ease pressure from soaring government debt, which recently surpassed $40 trillion. While these repurchases may reduce Treasury supply and stimulate the economy, they don...
